Sharing our research

We are committed to reporting the results of clinical research that evaluates our medicines and vaccines, irrespective of whether the outcomes are deemed to be positive or negative. In addition, we are being more open with our expertise, know-how and intellectual property around research into neglected tropical diseases.

Clinical study register

We are committed to public disclosure of all our clinical research, irrespective of whether the results are positive or negative for our medicines. We believe this is fundamental to the advancement of medical science. It is also the best way to tell prescribers and patients about scientific findings relating to our medicines.

Our Clinical Study Register website is a resource for researchers, medical professionals and the public to access data from GSK-sponsored clinical studies.

The register includes:

  • Protocol summaries for ongoing studies (a brief description of what is being researched and what the study is designed to discover)
  • Results from completed clinical studies on compounds that are both investigational and approved medicines
  • Results of observational research (studies of GSK medicines) and meta-analyses (which combine and analyse the results from two or more previous studies)
  • Results from studies of terminated medicines - this informs the scientific community about non-productive areas of research and may reduce exposure of volunteers to similar compounds
  • Names of principal investigators who participate in our clinical research

Close

Patient-level data

An online system enables researchers to request access to anonymised patient level data that sit behind the results of clinical trials from a number of pharmaceutical companies, including GSK.  It is hoped that sharing these data with researchers will help to further scientific understanding and improve patient care.

This system will allow researchers to examine the study details more closely, do their own analyses and learn more about medicines and how they can best be used.  Consistent with good scientific practice, researchers will be required to submit a research plan and to commit to transparency in the publication of their work.

Close

Open innovation

To encourage innovation targeting diseases of the developing world - where there is not the same potential commercial return as in developed countries - we have changed the way we think about intellectual property and the way we work with others.

Our open innovation strategy is designed to promote change beyond GSK by sharing expertise, resources intellectual property and know-how with external researchers and the scientific community. Although the current focus is on disease of the developing world, we are already adapting open innovations models to apply to other areas of great medical need and scientific challenge including infectious and rare diseases.

Close